Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Research and Development Grants

University of Victoria

$44,750.00

Multifunctional cell microcarriers for high throughput cell culture and enzyme-free cell harvesting

FY 2018-19

Summary
RepliCel is a regenerative medicine company that develops autologous cell therapies to treat chronic tendinosis, UV-damaged or aged skin, and pattern baldness. The cells in this technology are isolated from skin biopsies that are obtained from patients, cultured in two-dimensional flasks for up to a month and a half, harvested using enzymes, and delivered in the patients using RepliCel's proprietary, next-generation injection device. Recently, the successful completion of its first-in-human clinical study of the Company's autologous cell therapy for the treatment of androgenetic alopecia (pattern baldness) was reported. As such, RepliCel seeks novel technologies to improve their cell culture process, which is currently time-consuming, labor-intensive, and low-throughput. The overarching goal of this collaborative research and development proposal is to develop an innovative platform that enables culturing a large number of adherent cells in small volumetric footprints is imperative for meeting lot requirements at different scales. *In this project, we will use a multifaceted approach that combines microfluidic technology, advanced materials, and drug delivery to grow cells in large quantities and harvest them without using cell-destructive enzymes. This technology will allow RepliCel to compete in the ever-increasing market of cell therapy approaches for the treatment of chronic tendinosis, damaged or aged skin, and pattern baldness. The proposed research is anticipated to result in significant economic gains for BC and Canada since the targeted technology applies to an emerging and strategic market. Innovations in this area can help reducing the costs associated with current cell-based treatment and transform the health and life sciences sectors.*
Program
Collaborative Research and Development Grants
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
513318-2017
Name nom
Akbari, Mohsen
Department département
Mechanical Engineering
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2017
Award amount
44750
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
1
Nb partie
1
Application title
Multifunctional cell microcarriers for high throughput cell culture and enzyme-free cell harvesting
Keyword
NSERC
Application summary
RepliCel is a regenerative medicine company that develops autologous cell therapies to treat chronic tendinosis, UV-damaged or aged skin, and pattern baldness. The cells in this technology are isolated from skin biopsies that are obtained from patients, cultured in two-dimensional flasks for up to a month and a half, harvested using enzymes, and delivered in the patients using RepliCel's proprietary, next-generation injection device. Recently, the successful completion of its first-in-human clinical study of the Company's autologous cell therapy for the treatment of androgenetic alopecia (pattern baldness) was reported. As such, RepliCel seeks novel technologies to improve their cell culture process, which is currently time-consuming, labor-intensive, and low-throughput. The overarching goal of this collaborative research and development proposal is to develop an innovative platform that enables culturing a large number of adherent cells in small volumetric footprints is imperative for meeting lot requirements at different scales. *In this project, we will use a multifaceted approach that combines microfluidic technology, advanced materials, and drug delivery to grow cells in large quantities and harvest them without using cell-destructive enzymes. This technology will allow RepliCel to compete in the ever-increasing market of cell therapy approaches for the treatment of chronic tendinosis, damaged or aged skin, and pattern baldness. The proposed research is anticipated to result in significant economic gains for BC and Canada since the targeted technology applies to an emerging and strategic market. Innovations in this area can help reducing the costs associated with current cell-based treatment and transform the health and life sciences sectors.*